Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-0.27% $3.65
America/New_York / 24 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 204.41 mill |
EPS: | -1.290 |
P/E: | -2.83 |
Earnings Date: | May 07, 2024 |
SharesOutstanding: | 56.00 mill |
Avg Daily Volume: | 0.264 mill |
RATING 2024-04-24 |
---|
B- |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Sell | |
Return On Asset: | Sell | |
DE: | Neutral | |
P/E: | Sell | |
Price To Book: | Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | ||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -2.83 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.48x |
Company: PE -2.83 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$0.0003 (-99.99%) $-3.65 |
Date: 2024-04-25 |
Expected Trading Range (DAY) |
---|
$ 3.40 - 3.90 ( +/- 6.93%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-25 | Schmid John P. | Buy | 17 809 | Common Stock |
2024-03-22 | Schmid John P. | Buy | 9 156 | Common Stock |
2024-03-25 | Berger Heather A. | Buy | 1 300 | Common Stock |
2024-03-13 | Kim Jae B. | Sell | 0 | Common Stock |
2024-03-13 | Kim Jae B. | Sell | 315 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
76.51 |
Last 96 transactions |
Buy: 40 774 561 | Sell: 39 424 073 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $3.65 (-0.27% ) |
Volume | 0.191 mill |
Avg. Vol. | 0.264 mill |
% of Avg. Vol | 72.49 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.